STOKE THERAPEUTICS INC(NASDAQ:STOK) stock News

STOK Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

23 days ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

a month ago - By: Benzinga

Where Stoke Therapeutics Stands With Analysts

2 months ago - By: Benzinga

A Look Ahead: Stoke Therapeutics's Earnings Forecast

23 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

a month ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

a month ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a month ago - By: Zacks Investment Research - Mentions: MRSN

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

a month ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

2 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

2 months ago - By: Zacks Investment Research - Mentions: MRUS

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Stoke Therapeutics, Inc. - Mentions: BIIB

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

3 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

3 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

4 months ago - By: Zacks Investment Research

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

5 months ago - By: Zacks Investment Research - Mentions: BRTX

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

5 months ago - By: Stoke Therapeutics, Inc.

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

5 months ago - By: Zacks Investment Research - Mentions: ALT HQY DOCS

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

5 months ago - By: Zacks Investment Research - Mentions: BIIB SAGE

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

5 months ago - By: Zacks Investment Research - Mentions: CGON

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

5 months ago - By: Investor's Business Daily - Mentions: BIIB

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar

5 months ago - By: Zacks Investment Research - Mentions: BPMC

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

5 months ago - By: Zacks Investment Research

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

6 months ago - By: Stoke Therapeutics, Inc.

STOKE THERAPEUTICS INC (STOK) Stock News

STOK Latest News, Press Relases and Analysis

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Where Stoke Therapeutics Stands With Analysts

A Look Ahead: Stoke Therapeutics's Earnings Forecast

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference